3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
10
Stomach Neoplasms
6
Colorectal Neoplasms
6
Biliary Tract Neoplasms
4
Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Gallbladder Neoplasms
2
Cholangiocarcinoma
2
Adenocarcinoma Of Esophagus
2
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Metastatic HER2-positive Breast Cancer
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
HER2-expressing Cancers
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Interventions
Cisplatin
253
Radiotherapy
176
Cetuximab
145
pembrolizumab
120
Docetaxel
97
Fluorouracil
92
Carboplatin
80
Paclitaxel
77
Radiotherapy, Intensity-Modulated
69
Nivolumab
37
Radiation
30
Drug Therapy
30
Erlotinib Hydrochloride
26
Gemcitabine
25
Cyclophosphamide
22
Gefitinib
21
Surveys and Questionnaires
20
Standard of Care
20
Surgical Procedures, Operative
19
Pemetrexed
19
durvalumab
18
Magnetic Resonance Spectroscopy
17
Capecitabine
17
Radiosurgery
16
Celecoxib
16
atezolizumab
15
Filgrastim
15
Amifostine
15
130-nm albumin-bound paclitaxel
15
fludarabine
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Head and Neck Neoplasms
×
zanidatamab
×
Clear all
NCT07192068
2025-12-19
AcSé HER2
UNICANCER
Phase 2
Recruiting
105 enrolled